PSI
GNMX

Pinnacle Summer Investments’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Pinnacle Summer Investments’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-5,250
Closed -$31K – 1021
2013
Q4 		$31K Sell
5,250
-6,000
-53% -$39.2K ﹤0.01% 530
2013
Q3 		$88K Buy
+11,250
New +$52.2K 0.02% 352

Other funds holding GNMX

Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pinnacle Summer Investments's GNMX Position: Q1 2014 in Review

Pinnacle Summer Investments sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2014, closing a stake of 5,250 shares — an estimated $31K sold.

Pinnacle Summer Investments first reported a position in GNMX in Q3 2013 and held it in 2 quarters. The position peaked at $88K in Q3 2013. 28 funds tracked by Wall St. Rank hold GNMX as of Q1 2014.

  • Pinnacle Summer Investments reported no remaining Aevi Genomic Medicine Inc position as of Q1 2014 after selling out during the quarter.
  • Pinnacle Summer Investments sold 5,250 Aevi Genomic Medicine Inc shares in Q1 2014, an estimated $31K.
  • Pinnacle Summer Investments first reported a position in Aevi Genomic Medicine Inc in Q3 2013 and held it in 2 quarters.
  • Pinnacle Summer Investments's Aevi Genomic Medicine Inc position peaked at $88K in Q3 2013.
  • 28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2014.

Based on Pinnacle Summer Investments's 13F filing for Q1 2014, filed 16 May 2014.